Differential Diagnosis of the Refractory Gastroesophageal Reflux Diseases
Authors:
K. Lukáš; A. Žák
Authors‘ workplace:
IV. interní klinika 1. LF UK a VFN, Praha
Published in:
Čas. Lék. čes. 2008; 147: 599-606
Category:
Review Article
Overview
Refractory gastroesophageal reflux disease is a condition which develops when the reflux of stomach contents causes troublesome symptoms and/or complications. Despite bi-daily administration of proton pump inhibitors, reflux symptoms may persist, new symptoms may occur or become unmasked, and oesophagitis can fail to heal. Some of these patients do not take their medications, well-defined pharmacokinetic factors or genetic polymorphisms can contribute, nonacid reflux can be the culprit or their oesophagitis and/or symptoms may not be due to acid reflux. The first investigation to perform in the refractory gastroesophageal reflux disease is the upper endoscopy to exclude the possibility of refractory peptic ulcer disease or, less likely, cancer, and to identify „other“ oesophagitis (nonerosive alternative oesophagitis – microscopic oesophagitis).
Key words:
refractory gastroesophageal reflux disease, erosive oesophagitis, non-erosive oesophagitis, proton pump inhibitor.
Sources
1. The Montreal Definition and Classification of Gastroesophageal Reflux Disease: A Global Evidence-Based Consensus. Amer. J. Gastroenterol., 2006, 101, s. 1900–1920.
2. Richter, J. E.: The patient with refractory gastroesophageal reflux disease. Dis. Esoph., 2006, 19, s. 443–447.
3. Richter, J. E.: How to manage refractory GERD. Nat. Clin. Pract. Gastroenterol. Hepatol., 2007, 4, s. 658–664.
4. Fornari, F., Sifrim, D.: Diagnostic options for patients with refractory GERD. Curr. Gastroenterol Rep., 2008, 10, s. 283–288.
5. Becker, V., Bajbouj M., Walter, K. et al.: Clinical trial: persistent gastro-oesophageal reflux symptoms despite standard therapy with proton pump inhibitors – a follow-up study of intraluminal-impedance guided therapy. Aliment. Pharmacol. Ther., 2007, 26, s. 1355–1360.
6. Bredenrood, A. J., Dent, J.: Proton pump inhibitor-therapy refractory gastroesophageal reflux disease patients, who are they? Gut, 2007, 56, s. 593–600.
7. Tytgat, G. N. J.: Esophagology 2008: any progress? Curr. Opinion. Gastroenterol., 2008, 24, s. 482–484.
8. Fass, R., Gasiorowska, A.: Refractory GERD: what is it? Curr. Gastroenterol. Rep., 2008, 10, s. 252–257.
9. Bardham, K. D.: The role of proton pump inhibitors in the treatment of gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther., 1995, 9, s. 15–25.
10. Chen, J., Xu, J., Xu, Y., et al.: Analysis on the causes for refractory GERD. J. Huazhong Univ. Sci. Technolog. Med. Sci., 2002, 22, s. 47–49.
11. Tutuian, R., Vela, M. F., Hill, E. G. et al.: Characteristics of symptomatic reflux episodes on Acid suppressive therapy. Am. J. Gastroenterol., 2008, 103, s. 1090-1096.
12. van Malenstein, H., Farré, R., Sifrim, D.: Esophageal dilated intercellular spaces (DIS) and nonerosive reflux disease. Am. J. Gastroenterol., 2008, 103, s. 1021–1028.
13. Harrison, A. F., Jarboe, L. A., Weinberg, B. M. et al.: Patterns of proton pump inhibitors in clinical practice. Am. J. Med., 2001, 111, s. 469–473.
14. Pohle, T., Domschke, W.: Results of short- and long-term. Medical treatment of gastroesophageal reflux disease. Langenbeck’s Arch. Surg., 2004, 385, s. 2435–2443.
15. Katz, P. O.: Medical therapy for gastroesophageal reflux disease in 2007. Rev. Gastroenterol. Disord., 2007, 7, s. 193–203.
16. Charbel, S., Khandwala, F., Vseti, M. F.: The role of esophageal pH monitoring in symptomatic patients on PPI therapy. Am. J. Gastroenterol., 2005, 100, s. 283–289.
17. Mackalski, B. A., Ilnyckyj, A.: Esophageal pH testing in patients refractory to proton pump inhibitor therapy. Can. J. Gastroenterol., 2008, 22, s. 249–252.
18. Pandolfino, J. E., Richter, J. E., Ours, T. et al.: Ambulatory esophageal pH monitoring using a wireless system. Am. J. Gastroenterol., 2003, 98, s. 740–749.
19. Vseti, M. F., Lacamera, R. G., Richter, J. E.: Validation studies of Bilitec 2000: an ambulatory duodenogastric reflux monitoring system. Am. J. Physiol. Gastrointest. Liver Physiol. 1994, 267, s. G1050–G1057.
20. Koek, G. H., Vos, R., Flamen, P. et al.: Oesophageal clearance of acid and bile: a combined radionuclide, pH, and Bilitec study. Gut, 2004, 53, s. 21–26.
21. Oommen, J., Birk, G., Walker, D. et al.: The Bravo pH Capsule Reviewed, An Analysis of the Safety and Performance in 342 Cases.Gastrointest. Endosc., 2006, 63, s. AB244.
22. Fornari, F., Sifrim, D.: Diagnostic options for patients with refractory GERD. Curr. Gastroenterol. Rep., 2008, 10, s. 283–288.
23. Blackstone, M. O.: In: Endoscopic Interpretations. New York, Raven Press, 1984, s. 24–33.
24. Parkman, H. P., Cohen, S.: Heartburn, Regurgitation, Odynophagia, Chest Pain, and Dysphagia. In: Bockus Gastroenterology. Haubrich, S. W., Schaffner, F., Berk, J. E. eds. Philadelphia, W. B. Saunders Comp., 1995, s. 30–40.
25. Abid, S., Mumtaz, K., Jafri, W. et al.: Pill-induced esophageal injury: endoscopic features and clinical outcomes. Endoscopy, 2005, 37, s. 740–744.
26. Geagea, A., Cellier, C.: Scope of drug-induced, infectious and allergic esophageal injury. Curr. Opin. Gastroenterol., 2008, 24, s. 496–501.
27. Štork, J.: Dermatovenerologie. Praha, Galén Karolinum, 2008.
28. Keate, R. F.: Lichen planus: report of three patients treated with oral tacrolimus or intraesophageal corticosteroid injection or both. Dis. Esoph., 2003, 16, s. 47–53.
29. Miller, L. S., Vinarek, R., Krucht, H. et al.: Reflux esophagitis in patients with the Zollinger-Ellison syndrome. Gastroenterology, 1990, 98, s. 341–346.
30. Furuta, T., Shirai, N., Watanabe, F. et al.: Effect of the cytochrome P45O2C19 genotypic diffrences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin. Pharmacol. Ther., 2002, 72, s. 453–460.
31. Schwab, M., Klotz, U., Hofmann, U. et al: Esomeprazole induced healing of gastroesophageal reflux disease is unrelated to the genotype CYP2C19: Evidence from clinical and pharmacokinetic data. Clin. Pharmacol. Ther., 2005, 78, s. 627–634.
32. Fox, V. L., Nurko, S., Furuta, G. T.: Eosinophilic esophagitis: it’s not just kids stuff. Gastrointest. Endosc., 2002, 56, s. 260–270.
33. Sgouros, S. N., Mantides, A.: Refractory Heartburn to Proton Pump Inhibitors: Epidemiology, Etiology and Management. Digestion, 2006, 73, s. 218–226.
34. Egan, L. J., Myhre, G. M., Mays, D. C. et al.: CYP2C19 pharmacogenetics int the clinical use of proton-pump inhibitors for gastro-oesophageal reflux disease: variant alleles predict gastric acid supression, but no oesophageal acid exposure or reflux symptoms. Aliment. Pharmacol. Ther., 2003, 17, s. 1521–1528.
35. Pasha, S. F., DiBaise, J. K., Kim, H. J. et al.: Patient characteristics, clinical, endoscopic, and histologic findings in adult eosinophilic esophagitis: a case series and systematic review of the medical literature. Dis. Esoph., 2007, 20, s. 311–319.
36. Miller, S., Pohl, S., Vieth, M. et al.: Analysis of symptoms and endoscopic findings in 117 patients with histological diagnoses of eosinophilic esophagitis. Endoscopy, 2007, 39(4), s. 339–344.
37. Chehade, M., Sampson, H. A.: Epidemiology and etiology of eosinophilic esophagitis. Gastrointest. Endosc. Clin. N. Am., 2008, 18, s. 33–44.
38. Morrow, J. B., Vargo, II. J. J. , Goldblum, J. R. et al.: The ringed esophagus: histological features of GERD. Am. J. Gastroenterol., 2001, 96, s. 984–989.
39. Ngo, P., Furuta, G. T., Antoniovi, D. A. et al.: Eosinophils in the esophagus-peptic or allergic eosinophilic esophagitis? Case series of three patients with esophageal eosinophilia. Am. J. Gastroenterol., 2006, 101, s. 1666–1670.
40. Straumann, A.: Natural history of primary eosinophilic esophagitis: a follow-up of 30 adult patients for up to 11.5 years. Gastroenterology, 2003, 125, s. 1660–1669.
41. Teitelbaum, J., Fox, V., Twarog, F. et al.: Eosinophilic esophagitis in children: immunopathological analysis and response to fluticasone propionate Gastroenterology, 2002, 122, s. 1216–1225.
42. Konikoff, M., Noel, R., Blanchard, C. et al.: A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis. Gastroenterology, 2006, 131, s. 1381–1391.
43. Peghini, P., Katz, P., Castell, D.: Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology, 1998, 115, s. 1335–1339.
44. Kraichely, R. E., Farrugia, G.: Achalasia: physiology and ethiopathogenesis. Dis. Esoph., 2006, 19, s. 213–223.
45. Smout, A. J. P. M.: Advances in esophageal motor disorders. Curr. Opin. Gastroenterol., 2008, 24, s. 485–489.
46. Portale, G., Costantini, M., Zaninotto, G. et al.: Pseudoachalasia: not only esophago-gastric cancer. Dis. Esoph., 2007, 20, s. 168–172.
47. Šetka, J., Mařatka, Z.: Jícen a kardie. In: Klinická gastroenterologie. Praha, Avicenum, 1988, s. 148–196.
48. Wong, R. K. H., Maydonovitch, C. L.: Achalasia. In: Castell, D.O.: The Esophagus. Philadelphia, Lippincott Williams & Wilkins, 1999, s. 185–213.
49. Fackler, W., Ours, T., Vseti, M. et al.: Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology, 2002, 122, s. 625–632.
50. Scarpignato, C., Polosni, I.: Review artcicle: the opportunities and benefits of extended acid suppresion. Aliment. Pharm. Ther., 2006, S2, s. 23–34.
51. Sifrim, D., Holloway, R., Silny, J. et al.: Acid, non-acid, and gas reflux in patients with gastro-esophageal reflux disease during ambulatory 24-hour pH-impedance recordings. Gastroenterology, 2001, 120, s. 1588–1598.
52. Rackoff, A., Agrawal, A., Hila, A. et al.: Histamine-2 receptor antagonists at night improve gastroesophageal reflux disease symptoms for patients on proton pump inhibitor therapy. Dis. Esoph., 2005, 18, s. 370–373.
53. Grossmann, D. A.: The Functional Gastrointestinal Disorders and the Rome III Process. Gastroenterology, 2006, 130, s. 1377–1390.
54. Barlow, W. J., Orgando, R. C.: The Pathogenesis of Heartburn in Nonerosive Reflux Disease: A Unifying Hypothesis. Gastroenterology, 2005, 128, s. 771–778.
55. DeVault, K. R.: Review article: the role of acid supression in patients with non-erosive reflux disease or functional heartburn. Aliment. Pharm. Ther., 2006, 23 (Suppl. 1), s. 33–39.
56. Anders, A., Kott, A.: Sertralinum. Remedia, 2004, 14, s. 11–17.
57. Hirano, I.: Review article: modern technology int the diagnosis of gastroesoophageal reflux disease – Bilitec, intraluminal impedance and Bravo capsule pH monitoring. Aliment. Pharm. Ther., 2006, 23(Suppl. 1), s. 12–24.
58. Galmiche, J., Clouse, R, Bálint, A. et al.: Functional esophageal disorder. Gastroenterology, 2006, 130, s. 1459–1465.
59. Kikendall, J. W.: Pill-induced esophageal injury. In: Castell, D. O., Richter, J. E. eds.: The Esophagus. Philadelphia, Lippincott Williams & Wilkins, 2004, s. 572–584.
60. Kahrilas, P. J.: Gastroesophageal reflux disease. N. Engl. J. Med., 2008, 359, s. 1700–1707.
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain managementArticle was published in
Journal of Czech Physicians
Most read in this issue
- Differential Diagnosis of the Refractory Gastroesophageal Reflux Diseases
- Hostility as the Risk Factor for Many Health Problems and Its Management
- Lenalidomid (Revlimid) in the Treatment of Multiple Myeloma – First Experience in the Czech Republic
- Pendred Syndrome Among Patients with Hypothyroidism: Genetic Diagnosis, Phenotypic Variability and Occurrence of Phenocopies